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Abstract
Background: Biofilm formation is a major virulence factor contributing to the chronicity of infections. To date few
studies have evaluated biofilm formation in infecting isolates of patients including both Gram-positive and
Gram-negative multidrug-resistant (MDR) species in the context of numerous types of infectious syndromes. Herein,
we investigated the biofilm forming capacity in a large collection of single patient infecting isolates and compared
the relationship between biofilm formation to various strain characteristics.
Methods: The biofilm-forming capacity of 205 randomly sampled clinical isolates from patients, collected from
various anatomical sites, admitted for treatment at Brooke Army Medical Center (BAMC) from 2004–2011, including
methicillin-resistant/methicillin susceptible Staphylococcus aureus (MRSA/MSSA) (n=23), Acinetobacter baumannii
(n=53), Pseudomonas aeruginosa (n=36), Klebsiella pneumoniae (n=54), and Escherichia coli (n=39), were evaluated for
biofilm formation using the high-throughput microtiter plate assay and scanning electron microscopy (SEM).
Relationships between biofilm formation to clonal type, site of isolate collection, and MDR phenotype were
evaluated. Furthermore, in patients with relapsing infections, serial strains were assessed for their ability to form
biofilms in vitro.
Results: Of the 205 clinical isolates tested, 126 strains (61.4%) were observed to form biofilms in vitro at levels
greater than or equal to the Staphylococcus epidermidis, positive biofilm producing strain, with P. aeruginosa and S.
aureus having the greatest number of biofilm producing strains. Biofilm formation was significantly associated with
specific clonal types, the site of isolate collection, and strains positive for biofilm formation were more frequently
observed to be MDR. In patients with relapsing infections, the majority of serial isolates recovered from these
individuals were observed to be strong biofilm producers in vitro.
Conclusions: This study is the first to evaluate biofilm formation in a large collection of infecting clinical isolates
representing diverse types of infections. Our results demonstrate: (1) biofilm formation is a heterogeneous property
amongst clinical strains which is associated with certain clonal types, (2) biofilm forming strains are more frequently
isolated from non-fluid tissues, in particular bone and soft tissues, (3) MDR pathogens are more often biofilm
formers, and (4) strains from patients with persistent infections are positive for biofilm formation.
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Background
Multidrug-resistant (MDR) organisms, including Acineto-
bacter baumannii, methicillin-resistant Staphylococcus
aureus (MRSA), and extended spectrum beta-lactamase
(ESBL) producing Gram-negative bacteria, are frequently
implicated as the causative agents of acute and chronic
infections contributing significantly to patient morbidity
and mortality, as well as increased health care costs asso-
ciated with treatment [1,2]. Numerous studies to date indi-
cate that human infections are, in large part, caused by the
ability of bacteria to develop surface attached polymicrobial
communities known as biofilms [3-5]. Microbial biofilms
consist of groups of bacterial cells adherent to a surface
and enclosed within a self produced extracellular matrix
[6]. Adaptation to surface attached growth within a biofilm
is accompanied by significant changes in gene and protein
expression, as well as metabolic activity [7,8] which confers
resistance to antimicrobial therapy [9,10] and host
mechanisms of clearance [11,12]. Many pathogenic
and nosocomial bacteria have been observed to pre-
dominantly exist as biofilms, in both natural environments
and within infected tissues as polymicrobial communities
[4,5,13-15]. Importantly, biofilm formation is implicated as
a significant factor involved in a number of chronic human
infections [4,16,17].
Although there are numerous studies to date describing
the ability of clinical strains to form biofilms in vitro
(Additional file 1), these have varied widely in their study
design, method of characterizing isolates and their
biofilms, strains and number of isolates used, and most
have omitted molecular assessments of strain relatedness
to ensure a genetically heterogeneous sample and link
biofilm production to strain type, with the exception of
few studies evaluating biofilm formation and SCCmec and
spa typing in staphylococci [18-22]. Likewise, few studies
have surveyed biofilm formation among Gram-negative
clinical isolates outside the context of genitourinary tract
infections [23,24]. Furthermore, to our knowledge although
biofilms have been implicated to be involved in chronic
infections, no studies have characterized biofilm production
from isolates recovered from relapsed infections where the
clonal identity was proven identical to the initial infecting
strains. Herein, we evaluated the biofilm forming capacity
in a large collection of single-patient bacterial isolates,
representing both Gram-positive and Gram-negative
bacterial species, recovered from patients admitted for
Table 1 Characteristics of clinical isolates used in this study
Bacterial species Clinical isolates # of patients Pulsed- Field Type (PFTs) *Phenotype Site of isolation
E. coli 39 32 1 (n=4) ESBL+ (n=31) Wound culture (n=10)
2 (n=5) Blood (n=4)




K. pneumoniae 54 33 1 (n=6) MDR (n=54) Wound culture (n=39)
2 (n=8) Blood (n=10)
3,4,14,16,17, 18 (n=5) Respiratory (n=5)
Other (n=10)
P. aeruginosa 36 17 1 (n=7) MDR (n=28) Wound culture (n=29)
2, 18 (n=5) Blood (n=7)
Other (n=19)
A. baumannii 53 47 1 (n=13) MDR (n=46) Wound culture (n=31)
5 (n=4) Blood (n=20)
2,3,4, 6,7,14 (n=5) Urine (n=1)
Other (n=6) Respiratory (n=1)
S. aureus 23 21 USA100 (n=10) MRSA (n=15) Wound culture (n=14)
USA200, USA800 (n=4) MSSA (n=8) Blood (n=4)
USA300 (n=2) Respiratory (n=5)
USA700 (n=3)
*A multidrug-resistant (MDR) organism was defined as any extended spectrum beta-lactamase (ESBL)-producing bacteria, or if resistant to all tested antimicrobials
in 3 or more classes of antimicrobial agents (penicillins/cephalosporins, carbapenems, aminoglycosides, and quinolones) not including tetracyclines or colistin.
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Figure 1 Biofilm formation by clinical bacterial isolates. Biofilm formation by individual clinical isolates of E. coli (n=39), P. aeruginosa (n=36),
S. aureus (n=23), K. pneumoniae (n=54), and A. baumannii (n=53) using the 96-well microtiter plate assay. Biofilm formation was assessed by
staining the attached bacteria with 0.1% CV and measuring the OD values at 570nm (CV570) after 48 h growth at 37°C. Bars are representative of
the average biofilm biomass from three independent experiments for each clinical isolate tested. Error bars indicate the standard error. Dashed
line (−−-) indicates average biofilm biomass value (OD570 = 0.122) for S. epidermidis ATCC 12228, the positive control for biofilm formation. Bars
representing individuals strains are color coded to indicate site of isolation. Clinical isolates were ordered randomly with the exception of S.
aureus which was separated by methicillin resistant (MRSA) and sensitive (MSSA) strains.
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treatment at our medical facility for numerous types of
infectious syndromes. Additionally, the biofilm formation
phenotype was evaluated in the context of relapsing
infection, where serial isolates were available for study.
Methods
Bacterial isolates and growth conditions
The 205 clinical isolates used in this study were selected
from a strain repository at Brooke Army Medical Center
(BAMC; Fort Sam Houston, TX, USA). Bacterial strains
from the repository were collected from patients as part
of the standard care and infection control policy not
related to research from 2004–2011. The 205 single and
serial clinical isolates were randomly selected from the
strain collection representing a total of 150 patients and
multiple anatomical collection sites, including wound
cultures, bone, respiratory tract, urine and blood (Table 1).
As a positive control for biofilm formation, the previously
characterized biofilm forming strain S. epidermidis ATCC
strain 12228 was used [25,26]. Bacterial cultures were
frozen and maintained at −80°C and sub-cultured on blood
agar plates (Remel, Lenexa, KS) overnight at 37°C prior to
each experimental assay. With the exception of S. aureus,
which was cultured in tryptic soy broth (TSB), all bacteria
were grown in Luria-Bertani broth (LB) overnight at 37°C.
Antimicrobial susceptibility testing for all strains was
Figure 2 Scanning Electron Microscopy (SEM) images of biofilms. Representative SEM images of biofilms established on polystyrene pegs
following 48 h incubation at 37°C from a selected biofilm producing strain of each bacterial species; including A) S. epidermidis ATCC 12228
(positive control), B) E. coli, C). P. aeruginosa, D) S. aureus (MRSA), E) S. aureus (MSSA), F) K. pneumoniae, and G) A. baumannii. SEM pictures were
taken at 2000X magnification; inset white bar is representative of 10 microns.
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performed using the BD Phoenix™ automated microbiology
system as recommended by the manufacturer (BD, Franklin
Lakes, NJ). Resistance and susceptibilities to the various
drugs tested are reflective of the clinical breakpoints set
by the Clinical and Laboratory Standards Institute (CLSI)
as described by the performance standards for antimicro-
bial susceptibility testing (M100-S22, Jan 2012).
Pulsed-field gel electrophoresis (PFGE)
Clonal relationships between bacterial strains of each
individual species were assessed by pulsed-field gel
electrophoresis (PFGE) according to the FDA method
‘Procedure for PFGE of Gram-negative rods’ (Version 1,
10/30/2007) and as previously described using the CHEF-
DRIII system (Bio-Rad Laboratories, Hercules, California)
[27,28]. The endonuclease ApaI was used for A. baumannii
PFGE, SmaI for MRSA PFGE, XbaI for K. pneumoniae
and E. coli PFGE and SpeI was used for P. aeruginosa
PFGE. Gel images were analyzed using BioNumerics
software (Applied Maths, Austin, TX). PFGE patterns
were interpreted and grouped into pulsed field types
(PFTs) using previously established criteria [27,29].
Biofilm formation in 96-well microtiter plates
Biofilm formation was examined by the semi-quantitative
determination of biofilm formation in 96-well flat bottom
plates as previously described [30,31]. Briefly, fresh bacterial
suspensions were prepared in either TSB or LB from
overnight cultures and adjusted to OD600 of 0.1 (~ 10
7
CFU/mL). 100 μL aliquots of bacterial suspension were
then inoculated into individual wells of a 96-well flat-
bottomed polystyrene plate and incubated overnight at
37°C for 48h. Following overnight incubation, plates
were gently washed with 1X phosphate buffered saline
(PBS; pH 7.4) and stained with 100 μL of 0.1% Crystal
Violet (Sigma-Aldrich, St. Louis, MO) for 30 min at room
temperature. Excess crystal violet was removed by
washing, and biofilm was quantified by measuring the
corresponding OD570 nm of the supernatant following the
solubilization of CV in 95% ethanol. For each clinical
strain tested, biofilm assays were performed in triplicate
and the mean biofilm absorbance value was determined.
Strains that formed biofilms ≥ OD570 of the positive control
were considered to be positive for biofilm formation
whereas those strains with values less than the control were
considered as weak biofilm forming strains.
Figure 3 Association between biofilm formation and pulsed-field type. Relationship of the biofilm-forming capacity of individual strains and
pulsed-field type (PFT). Data points represent the mean biofilm biomass of individual isolates tested from each of the unique PFTs, as determined
by the microtiter plate assay. Line bar represents the median biofilm biomass for each PFT group. Only pulsed-field types with >3 individual
strains were used for the comparison. Other denotes those groups with <3 clinical isolates. Error bars represent the standard deviation among
the results for different isolates. One-Way ANOVA analysis with Holm-Sidak comparison test was used to determine statistical differences between
groups. Asterisks indicate those groups that were statistically significant to the majority of PFT; *p<0.05.
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Visualization of biofilms by Scanning-Electron Microscopy
(SEM)
A single representative strain from each of the individual
bacterial species demonstrating significant biofilm
formation based on the microtiter plate assay, were
further characterized by SEM. Bacterial biofilms were
grown on polystyrene pegs using the MBEC™-P&G plates
(Innovotech, Alberta, Canada) for 48h, following the
methods described above, and SEM was performed using
previously described optimized conditions [32,33]. Briefly,
following incubation, pegs were rinsed with 1X PBS and
removed using sterile needle-tipped pliers. Each peg
was then fixed with 2% (w/v) glutaraldehyde, 2% (w/v)
paraformaldehyde, 0.15 M sodium cacodylate, 0.15%
(w/v) alcian blue for 3 hr at room temperature. Pegs were
then rinsed three times with 0.15 M sodium cacodylate
buffer, immersed in 1% (v/v) osmium tetroxide in sodium
cacodylate and incubated for 1 hr at room temperature.
Pegs were then rinsed three times with distilled water
followed by a stepwise dehydration with ethanol (i.e. 70%,
95%, and 100%). Samples were then treated with hexam-
ethyldisilizane for 5 min prior to drying in a desiccator
overnight. Next day samples were sputter coated with
gold palladium and viewed with a JEOL-6610 scanning
electron microscope. SEM experiments were carried out
in duplicate for each strain tested, and representative
images of biofilms were selected.
Statistical analysis
Statistical analysis was performed using One-way ANOVA
with a Holm-Sidak post-hoc evaluation for comparison
between multiple groups. For non-parametric comparisons
between groups, the Χ2 test was performed. P values of
<0.05 were considered to be statistically significant.
Results and discussion
Clinical strains have a heterogeneous capacity for biofilm
formation
The ability of clinical isolates to form biofilms is associated
with the capacity of these organisms to survive within
hospital environments, on implanted medical devices,
and in the wounds of patients [4,16,17]. The majority of
studies examining biofilm formation in clinical isolates
to date have focused primarily on isolates representative of
bacterial species associated with device related infections
(Additional file 1). Consequently, limited studies on biofilm
formation in certain bacterial species, including A.
baumannii and K. pneumoniae, associated with other
clinical diseases are available. To address this, we evaluated
the ability of individual clinical isolates from a diverse
collection of infecting isolates to develop biofilms using
the semi-quantitative 96-well plate assay as described
[30,34,35]. This static model of biofilm formation has been
demonstrated to be a reliable and a reproducible method
for assessing biofilm formation in vitro. Of the 205 clinical
strains evaluated for biofilm formation, more than half of
all isolates (61.4%; 126/205) were observed to be capable of
forming biofilms equal to or greater than the biofilm
control strain, S. epidermidis ATCC 12228 (Figure 1). As
shown in Figure 1, biofilm formation by individual isolates
was heterogeneous and dependent on both the bacterial
species and strain.
Figure 4 Biofilm formation is associated with the site of
isolation. A) Distribution of biofilm-forming strains among fluid or
non-fluid culture source. Bars are representative of % biofilm positive
strains. Statistical analysis was performed using the X2 test.
B) Comparison of biofilm biomass (CV570) from clinical isolates
collected from various anatomical sites, including urine (n=27),
blood (n=45), tissue deep (n=82), tissue superficial (n=31), bone
(n=8) and respiratory sites (n=12), as determined by the microtiter
plate assay. Data points represent the average biofilm biomass of
individual isolates tested from each anatomical site and line bar
represents the median biofilm biomass of the group. One-Way
ANOVA analysis with Holm-Sidak comparison test was used to
determine statistical differences between groups. Asterisks indicate
those groups that were statistically significant; *p<0.05.
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Table 2 Biofilm formation and antimicrobial resistance in clinical isolates
A. baumannii E. coli K. pneumoniae P. aeruginosa S. aureus
n=53 n=39 n=54 n=36 n=23
% MDRa 86.7%; 46/53 79.5%; 31/39 100% 77.7%; 28/36 65.2%; 15/23
Antimicrobial %b %Biofilm
Production







Amikacin R 67 65 10 33 20 83 25 67 ND ND
S 33 47 90 15 80 50 75 81 ND ND
Gentamicin R 90 89 47 14 93 79 39 75 3 100
S 10 67 53 19 7 71 61 59 97 90
Tobramycin R 70 81 53 19 53 81 23 90 ND ND
S 30 33 47 14 47 64 77 78 ND ND
Ansamycins
Rifampin R ND ND ND ND ND ND ND ND 0 92
S ND ND ND ND ND ND ND ND 100 78
Cephalosporins
Cefazolin R ND ND 93 14 90 67 100 80 69 99
S ND ND 7 50 10 0 0 0 31 50
Cefepime R ND ND 77 9 93 82 63 79 ND ND
S ND ND 23 43 7 56 37 82 ND ND
Cefoxitin R ND ND 10 67 13 100 100 80 74 95
S ND ND 90 11 87 65 0 0 26 60
Cefotaxime R 80 63 ND ND 93 68 ND ND ND ND
S 20 50 ND ND 7 100 ND ND ND ND
Ceftazidime R 53 44 77 13 97 86 67 90 ND ND
S 47 93 23 29 3 33 33 60 ND ND
Ceftriaxone R ND ND 80 13 87 73 100 80 ND ND
S ND ND 20 33 13 69 0 0 ND ND
Carbepenems
Imipenem R 67 85 0 0 0 0 75 86 ND ND
S 33 30 100 17 100 70 25 95 ND ND
Meropenem R 67 85 0 0 0 0 58 78 ND ND
S 33 30 100 17 100 70 42 82 ND ND
Flouroquinolones
Ciprofloxacin R 90 85 83 12 63 79 75 80 ND ND
S 10 33 17 40 37 45 25 100 ND ND
Levofloxacin R 57 71 83 12 50 80 80 92 50 93
S 43 92 17 40 50 60 20 50 50 80
Penicillins
Ampicillin R 100 67 97 17 100 70 100 80 100 100
S 0 0 3 0 0 0 0 0 0 0
Aztreonam R 100 67 73 9 97 90 73 73 ND ND
S 0 0 27 38 3 100 27 100 ND ND
Oxacillin R ND ND ND ND ND ND ND ND 83 92
S ND ND ND ND ND ND ND ND 17 60
Piperacillin R 93 71 13 0 30 78 67 75 ND ND
S 7 100 87 19 60 61 33 90 ND ND
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Of the 23 S. aureus isolates tested, 21 strains (91%) were
positive for biofilm formation, with a median biofilm
biomass of 0.121 ± 0.074 and 0.161 ± 0.072 for MRSA and
MSSA, respectively. Consistent with previous reports, no
significant differences in biofilm formation between the
MRSA and MSSA strains were observed (p=0.40), indicat-
ing no significant correlation between methicillin suscepti-
bility and the ability to form biofilms [21,22]. In K.
pneumoniae, 41 of the 54 isolates tested (76%) were deter-
mined to be positive for biofilm formation with a median
biofilm biomass of 0.214 ± 0.118. Likewise, in P. aeruginosa
and A. baumannii, 30 of 36 (83%) and 29 of 53 (55%) of
clinical strains tested were observed to form biofilms with a
median biofilm biomass of 0.142 ± 0.094 and 0.125 ± 0.061,
respectively. In contrast, E. coli was the weakest biofilm
forming group with only 5 of the 39 strains (13%) capable
of forming biofilms greater than the control strain and
having the lowest biofilm biomass (median 0.044 ± 0.018).
As the majority of E. coli strains (64.2%) were collected
from fluid sites, blood (10.2%; 1 biofilm positive) and urine
(54%; 3 biofilm positive), and those strains positive for
biofilm formation were primarily from these sites, the low
prevalence of biofilm formation observed herein is likely
the result of the random sampling from our collection as
well as the strain types represented, discussed below, as
previous studies have demonstrated that clinical isolates of
E. coli are capable of forming biofilms in vitro [23].
Importantly for those strains that were observed to be poor
biofilm formers in vitro, these strains may still be important
during polymicrobial infections where they can directly be
incorporated into an established biofilm or interact with
other species providing synergy to the biofilm formers.
As confirmation of biofilm formation using the 96 well
plate model, we examined biofilm formation by scanning
electron microscopy (SEM) using the MBEC™-P&G
plates as previously described [32,33]. For this study,
single representative isolates from each species positive
for biofilm formation, as determined by the microtiter plate
method, were selected for SEM analysis. In agreement with
the results from the microtiter plate assay, SEM studies
demonstrated that the strains selected were capable of
forming mature, robust biofilms on the peg surface, albeit
the mature biofilm structures and phenotypes observed
were unique for each species (Figure 2A-G). Together
these findings demonstrate that biofilm formation is a
prevalent feature amongst clinical strains associated with
numerous infectious syndromes.
Relationship of biofilm formation to pulsed-field type and
culture site
The 205 isolates tested for biofilm formation herein
represented >29 unique PFTs in the five different bacterial
species, which were representative of the range of clinical
strains encountered within our healthcare treatment facility.
The pathogenic potential of numerous organisms has been
linked to the PFT. For example, MRSA USA300 has been
implicated in outbreaks within the US, accounting for up to
70% of all skin and soft tissue infections [36,37]. Given the
relationship between PFTand strain virulence, we evaluated
whether a similar association between biofilm formation
and PFT could be made.
Indeed, for each of the bacterial species evaluated
there was a significant association between specific PFT
groups and biofilm formation (Figure 3). In E. coli and
P. aeruginosa, clinical isolates belonging to PFT-2 (n=5)
(p<0.001) and PFT-18 (n=5) (p<0.001) groups respect-
ively, had a significantly greater ability to form biofilms,
as determined by crystal violet staining of biofilms,
compared to those strains within the other PFT groups.
In S. aureus, strains belonging to USA200 and USA 300
had a moderate, albeit insignificant, increased ability to
form biofilms compared to the other PFT. In contrast,
multiple PFTs in K. pneumoniae, including PFT-1 (n=6),
4, 14, 16, 17, and 18 (n=5), were associated with high
biofilm formation of which PFT-16 (n=5) (p<0.01) and
PFT-18 (n=5) (p<0.01) isolates were associated with the
greatest ability to form biofilms. In contrast, those
isolates belonging to PFTs 2 (n=8) and 3 (n=5) were weak
Table 2 Biofilm formation and antimicrobial resistance in clinical isolates (Continued)
Tetracyclines
Tetracycline R 80 71 67 20 63 58 ND ND 20 83
S 20 50 33 10 37 91 ND ND 80 88
Sulfonamides
Trimeth-Sulfameth R 90 78 77 17 73 86 100 80 0 0
S 10 50 23 14 27 50 0 0 1000 87
a A multidrug-resistant (MDR) organism was defined as any extented spectrum-lactamase (ESBL) producing bacteria, or if resistant to all tested antimicrobials on 3
or more classes of antimicrobial agent.
b %; indicates the percentage of isolates resistant (R) or sensitive (S) to each antimicrobial agent. Antimicrobial suceptibilities were determined using BD Phoenix™
automated microbiology system and are reflective of clinical breakpoints.
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biofilm forming strains. With the exception of PFTs-2
and 4 (n=5), the majority of the PFTs for A. baumannii
were also associated with biofilm formation of which
isolates from PFT-1 (n=13), 3, and 14 (n=5) (p<0.05)
groups were associated with a greater ability to form
biofilms. With the exception of a few studies evaluating
the relationship of biofilm formation to SSCmec and spa
typing in S. aureus, our study is the first to characterize
and identify PFT groups associated with biofilm formation
for K. pneumoniae, P. aeruginosa, and A. baumannii.
In addition to PFT, a strong correlation between biofilm
formation and the site of isolate collection was observed.
Table 3 Biofilm formation of serial isolates recovered from patients with clinical relapse involving clones identical to
the initial isolate
Patient Bacterium Isolate Source Days after initial isolate PFTa Biofilm former b
1 A. baumannii 1 Deep tissue 0 1 Yes
2 Deep tissue 3 1 Yes
3 Bone 8 1 Yes
4 Deep tissue 68 1 Yes
5 Deep tissue 70 1 Yes
6 Deep tissue 127 1 Yes
2 P. aeruginosa 1 Blood 0 1 Yes
2 Blood 1 1 Yes
3 Blood 17 1 Yes
4 Deep tissue 21 1 Yes
5 Pleural fluid 25 1 No
6 Deep tissue 29 1 Yes
7 Blood 36 1 Yes
8 Deep tissue 42 1 Yes
9 Respiratory tract 43 1 Yes
10 Blood 46 1 No
11 Respiratory tract 49 1 Yes
12 Blood 51 1 Yes
3 P. aeruginosa 1 Groin swab 0 A Yes
2 Superficial tissue 332 B No
3 Superficial tissue 332 B Yes
4 Deep tissue 522 A Yes
5 Deep tissue 522 A Yes
4 P. aeruginosa 1 Deep tissue 0 19 Yes
2 Deep tissue 158 19 Yes
5 MRSAc 1 Deep abscess 0 USA300 Yes
2 Deep abscess 0 USA300 Yes
3 Superficial abscess 16 USA300 Yes
4 Nares swab 105 USA300 Yes
5 Nares swab 161 USA300 Yes
6 Nares swab 202 USA300 Yes
7 Superficial fluid 224 USA300 Yes
8 Superficial tissue 247 USA300 Yes
9 Deep tissue 248 USA300 Yes
a Pulsed-field type (PFT).
b Strains with Crystal Violet absorbance greater than or equal to that of Staphylococcus epidermidis ATCC 12228 (positive control) were considered to be positive
for biofilm formation.
c Methicillin-resistant S. aureus.
Sanchez et al. BMC Infectious Diseases 2013, 13:47 Page 9 of 12
http://www.biomedcentral.com/1471-2334/13/47
Clinical strains isolated from non-fluid sites including
superficial/deep tissue, bone, and respiratory tract on
average had a significantly higher proportion of biofilm
positive strains compared to those isolates from host
fluids, including blood or urine (p=0.01) (Figure 4A).
Consistent with this, comparison of biofilm averages
amongst clinical strains grouped into individual collection
sites, demonstrated that isolates from superficial/deep
tissue, bone, and respiratory tract (i.e. non-fluid culture
sites) on average displayed enhanced biofilm formation,
as determined by CV measurement, compared to those
isolates from blood and urine (p<0.01) (Figure 4B). This
may reflect adaptations favoring the survival of organisms
in non-liquid physiologic environments, which may explain
in part the difficulty in eradicating some infections once
they become established in solid tissues. Of note, isolates
from bone, including S. aureus and K. pneumoniae, had a
significantly greater ability to form biofilms compared to
the isolates collected from respiratory, superficial, and deep
tissue groups (p=0.04,p=0.02 and p<0.001 respectively).
Together these findings implicate that at various
anatomical sites, such as bone and soft tissue, biofilm for-
mation may play a role in the successful colonization and/
or the subsequent development of invasive disease at these
particular wound sites which is partly dependent on PFT.
Biofilm formation and multidrug-resistance
Antimicrobial resistance is an innate feature of bacterial
biofilms that, in addition to the increasing rates of
reported antimicrobial resistance amongst clinical strains,
may further complicate patient treatment [21,38]. In
comparing antimicrobial resistance to the ability of biofilm
formation in the individual strains, we observed that strains
capable of forming biofilms were more frequently observed
to be an MDR phenotype (Table 2). In A. baumannii,
strains capable of forming biofilms were more often
observed to be resistant to aminoglycosides, carbepenems,
tetracyclines, and sulfonamides compared to those strains
characterized as weak biofilm producers. Similarly in K.
pneumoniae and S. aureus, the ability to form biofilms was
observed in strains to be resistant to cephalosporins and
fluoroquinolones, respectively. Likewise, in P. aeruginosa
strains positive for biofilm formation more commonly
demonstrated a resistance phenotype to cephalosporins.
Because the majority of isolates selected to evaluate biofilm
formation were predominately MDR organisms, the inter-
pretations of these results are limited. However, as previous
studies have shown that biofilm formation is higher in
MDR strains [20,21,39], and can promote antimicrobial
resistance by selecting for highly resistant strains following
treatment with sub-inhibitory antimicrobial concentrations
[40,41], the ability of a strain to develop biofilms may have
an important, yet not fully understood role in the develop-
ment of multidrug resistance.
Biofilm formation among isolates from persistent
infections
As biofilm formation has been shown to be a mechanism
for evading host-defenses and resisting the effect of
antimicrobials, it has been suggested that strains capable
of forming biofilms may persist within the host contribut-
ing to relapsing/chronic infections [4,5,42]. Despite our
understanding of biofilms, few studies have provided
evidence directly implicating this phenotype in persistent
infections. To examine the relationship between biofilm
formation and relapsing infection, we assessed whether
serial isolates from five patients with persistent infections
were more likely to be positive for biofilm formation. In
all five of the patients, the duration between the first and
last isolate collection ranged from 0 to >100 days
(Table 3). In patients 2, 3, and 5 a number of the serial
isolates evaluated were collected from various sterile
anatomical sites unique to site of the first isolate. With
the exception of 3 of the isolates (3/34; 9%), the majority
of serial isolates (31/34; 91%) from the five patients were
positive for biofilm formation and was consistent between
the sequential isolates even those with recovery times >100
days apart, as determined by measurement of biofilm by
CV. The frequency of biofilm positive strains isolated from
patients with relapsing infections is interesting and
indicates a potential role for biofilm formation in these
types of infection; however, future studies evaluating larger
patient populations with relapsing infections and evaluating
additional clinical outcomes would be necessary to fully
evaluate the relationship between these two properties.
Conclusions
We found a high prevalence of biofilm-forming phenotypes
among a large number of clinical isolates representing a
diversity of species, genotypes and anatomic culture sites of
origin. In addition, biofilm formation was prevalent among
isolates with a MDR phenotype. To our knowledge, this
study is the first to demonstrate biofilm formation by serial
isolates recovered from relapsing clinical infections includ-
ing molecular characterizations of strain relatedness, and
contributes to a limited number of studies examining
biofilm formation by Gram-negative bacilli beyond the
context of urinary tract infections. Our findings highlight
the importance of the bacterial biofilm phenotype as a
potential virulence factor which may contribute to the
clinical relapse of infections.
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Additional file 1: Literature search of previous studies evaluating
biofilm formation by clinical isolates in vitro. List of previous studies
comparing biofilm formation by clinical isolates in various bacterial
species, emphasizing the focus of study, strains and methods used to
quantify biofilm formation, and conclusions drawn from studies.
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